Why promoter design is no longer just an expression checkbox, it’s the key to therapeutic endurance:
Advanced therapies Why promoter design is no longer just an expression checkbox, it’s the key…
What makes Annogen’s promoter design stand-out from other providers? A valid question. Let’s put this in historical context.
Gene promoter design is nothing new: as early as the 1980’s, researchers began to understand different components within promoters, e.g. TATA box and transcription factor binding sites. In parallel, the viral promoters still used today (CMV, CAG, …) were already in use.
Advancements in genomics and bioinformatics since the 2000s allowed for better understanding of tissue-specific gene expression and promoter functioning. This allowed scientists to construct #syntheticpromoters from scratch.
Using #AI and #machinelearning, many nowadays rely on the vast amounts of chromatin, transcriptional and functional genomics data to predict which regulatory sequences could be candidate promoters. Driven by innovation, Annogen is also levering such databases wherever possible.
Taken together, this means that we can design novel promoters elements based on your particular requirements for your #advancedtherapy and validate them before handing them over to you.
No other company provides validation, scale and precision at this level.
Leading pharma companies understand this and therefore trust us with their promoter design.
